We are a leading provider of critical reagents that enable the discovery, development and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Our 3,000 active customers span the continuum of the life sciences market, including leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our company is built around proprietary development and manufacturing processes that are highly adaptable and versatile. These proprietary processes enable us to manufacture and deliver high quality, custom, made-to-order products on a short turnaround time and at scale, across all stages of our customers’ product development, including commercialization.

(Note: Alpha Teknova upsized its IPO at pricing on June 24, 2021, to 6 million shares – up from 5 million shares in the prospectus – at $16 – the top of its $14-to-$16 price range – to raise $96 million.)